Q2 2023 Calliditas Therapeutics AB Earnings Call Transcript
Welcome to the Calliditas Therapeutics Q2 2023 report. (Operator Instructions) Now I'll hand over the conference to speakers; CEO, Renee Aguiar-Lucander; CFO, Fredrik Johansson; Andrew Udell, President of North America; and Richard Philipson, Chief Medical Officer. Please go ahead.
()-
Thank you very much, and welcome, everybody, to this Q2 report of 2023. I would just like to draw your attention to the disclaimer page related to forward-looking statements in the meaning of the Private Securities Litigation Reform Act of 1995 as amended. And I refer you to the company's reports and other regulatory filings including those which contain risk factors and other relevant information.
So I want to take you through some of the Q2 highlights. So in June of this year, we filed our supplemental NDA with the FDA, which is based on the full data from the NefIgArd Phase III trial. The trial successfully made its endpoint of kidney function as measured by eGFR
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |